# Contineum Therapeutics, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Contineum Therapeutics, Inc.).

## Overview

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for neuroinflammation and immunology (NI&I) indications with significant unmet need. Its lead programs are PIPE-791 for chronic pain and PIPE-307 for depression, with PIPE-307 being advanced in collaboration with Johnson & Johnson.

## Products & services

• PIPE-791 clinical program for chronic pain
• PIPE-307 clinical program for depression
• Small-molecule drug discovery for NI&I pathways
• Clinical development and regulatory advancement of pipeline assets
• J&J collaboration for PIPE-307 development

- **Clinical-stage drug candidates** (0%) — Lead therapeutic programs in development, including PIPE-791 and PIPE-307.
- **Collaboration revenue** (100%) — License and milestone economics tied to the J&J agreement for PIPE-307.
- **Research and development pipeline** (0%) — Internal discovery and preclinical work supporting future NI&I indications.

- PIPE-791 for chronic pain
- PIPE-307 for depression
- Small-molecule NI&I drug candidates
- Clinical-stage development programs
- J&J collaboration for PIPE-307

## Customers

Contineum does not sell approved commercial products today; its current counterparties are primarily development partners, regulators, clinical trial sites, CROs, CMOs, and investors funding the pipeline. If approved in the future, its end customers would be patients treated for chronic pain, depression, and other NI&I conditions, with reimbursement decisions influenced by payors.

- **Strategic collaboration partner** (primary) — Johnson & Johnson funds and supports PIPE-307 development under the license agreement.
- **Clinical development ecosystem** (primary) — CROs, investigators, laboratories, and CMOs that execute trials and manufacture clinical supply.
- **Regulatory authorities** (primary) — FDA and comparable agencies that review safety, efficacy, and manufacturing readiness.
- **Future patients and payors** (emerging) — Patients with chronic pain or depression and the insurers that would reimburse approved therapies.

- Johnson & Johnson as collaboration partner for PIPE-307
- Clinical trial sites and CROs supporting development execution
- CMOs and suppliers providing clinical manufacturing
- FDA and other regulators as approval gatekeepers
- Future patients and payors if programs reach commercialization

## Geography

Contineum is headquartered in San Diego, California, and its operating footprint is centered in the United States. The company disclosed office and laboratory leases in San Diego, while its future commercial exposure would likely broaden only if its drug candidates are approved and launched.

- Headquartered in San Diego, California
- Office and laboratory space concentrated in the U.S.
- Clinical development and regulatory work are U.S.-centric
- No disclosed country revenue mix because there is no product sales base
- Future commercialization could expand beyond the U.S. if approved

## Strategy

Contineum’s strategy is to advance a focused pipeline of selective small molecules for NI&I diseases, using PIPE-791 and PIPE-307 as the core value drivers. The company is prioritizing clinical execution, regulatory progress, intellectual property protection, and external financing while leveraging the J&J collaboration to reduce development burden on PIPE-307.

- **Advance clinical programs** (short-term) — Pipeline value depends on successful clinical data and regulatory milestones.
- **Secure financing** (short-term) — The company expects operating expenses to rise materially as trials expand.
- **Build IP and development infrastructure** (medium-term) — Patent protection and operational readiness are essential before commercialization.

- Advance PIPE-791 and PIPE-307 through clinical development
- Use selective small molecules to target challenging pathways
- Leverage the J&J collaboration to support PIPE-307
- Protect and expand intellectual property around the pipeline
- Raise capital to fund trials, headcount, and operations
- Prepare manufacturing and commercial capabilities if approved

## Risks

Contineum is highly dependent on two early-stage drug candidates, so clinical setbacks, safety issues, or regulatory delays could materially impair the business. Like other biopharma developers, it also faces financing risk, manufacturing and supply-chain risk, and payer/competitive pressure if products are ever approved.

- **Pipeline concentration** [critical] — The company is heavily dependent on two early-stage assets, so any failure would materially reduce prospects.
- **Clinical and regulatory failure** [high] — Drug candidates may not demonstrate efficacy, safety, or approvability in trials.
- **Financing and dilution** [high] — Operating losses and trial costs require ongoing capital raises before any product revenue exists.
- **Manufacturing and supply chain** [medium] — Clinical and future commercial supply depends on qualified third-party manufacturers and compliant facilities.
- **Competitive and reimbursement pressure** [medium] — Approved therapies for pain and depression include generics and established branded drugs, limiting pricing power.

- Heavy dependence on PIPE-791 and PIPE-307 success
- Clinical trial failure or delays could stop value creation
- Regulatory approval risk from FDA and foreign agencies
- Need for repeated financing before commercialization
- Manufacturing and CMO compliance can delay programs
- Future products may face generic and payor pricing pressure

## Accounting

The company’s reported results are driven mainly by collaboration revenue recognition, R&D expense accruals, stock-based compensation, and fair-value estimates for equity instruments. Because it is pre-commercial, small changes in milestone timing, clinical accruals, or financing-related valuations can materially affect quarterly results and comparability.

- **License revenue recognition** — Milestone timing can create lumpy quarterly revenue.
- **R&D accruals** — Changes in trial activity can shift expense recognition between periods.
- **Stock-based compensation** — Can materially affect operating expense and reported losses.
- **Fair value measurements** — Important around financing events and equity issuances.
- **Lease commitments** — Affects balance sheet liabilities and operating cash commitments.

- J&J license revenue depends on performance obligation timing
- R&D accruals affect period expense as trials and vendors are billed
- Stock-based compensation is a meaningful non-cash expense
- Fair value of common and preferred stock requires judgment
- Lease accounting reflects San Diego office and lab commitments

---

*Last updated: 2026-04-28T19:59:06.018303+00:00*